DRUG RESISTANCE AND GENE TRANSFER IN H PYLORI

幽门螺杆菌的耐药性和基因转移

• 批准号: 6532711
• 负责人: DOUGLAS Eugene BERG
• 金额: $ 25.97万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-01-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6532711
• 关键词: Helicobacter; bacterial genetics; clarithromycin; drug metabolism; drug resistance; gene expression; genetic recombination; host organism interaction; human tissue; laboratory mouse; metronidazole; mutagens; pathologic process; ribosomal RNA

Helicobacter pylori (HP) is a major cause of peptic ulcer disease and an early risk factor for gastric cancer. The two most widely used types of therapies against HP depend on metronidazole (Mtz) or clarithromycin (Cla), in combination with other agents, but resistance (R) to Mtz is common, and CIaR is also known. The resistance mechanisms that predominate in American and European populations have been identified: inactivation of a nitroreductase gene, rdxA (MtzR); and sequence changes in one segment of 23S rRNA. Our analyses of MtzR indicated that Mtz is a prodrug, activated (metabolized) by MtzS HP to hydroxylamine, a mutagen and a bacteriocidal agent. HP is an extremely diverse species, with each isolate readily distinguishable from most others. There are numerous duplicate and divergent genes in the HP genome. We suggest that recombination among these genes, gene transfer among different HP strains, and mutation, can all contribute to bacterial adaptation to different human hosts and in changing gastric environments, and more generally in the evolution of virulence. My long term goal is to understand how HP colonizes its human host, establishes infections that persist for years or decades, and in some cases cause overt disease; how it evolves as a human commensal and pathogen; and how best to combat the infections that it causes. Four sets of experiments are proposed: First, we will seek to better understand the emergence and persistence of drug resistance in HP populations. In these experiments, we will test the idea that mutations resulting in MtzR and/or CIaR diminish bacterial fitness (vigor of growth) in culture and in vivo in mouse infection models. Second, we will examine factors affecting the formation of recombinants in HP, with a special focus on duplicate and divergent genes. This will be modeled using alleles for CIaR, which occur in the 23S rRNA gene; there are two copies of the 23S rRNA gene per HP genome. We will examine transformation of HP to CIaR, and test factors determining if a given HP strain can exhibit a CIaR phenotype while being heterozygous for cIaR and cIaS alleles, vs. if if it must be cIaR/cIaR homozygous. Recombination will also be examined using "synthetic merozygotes", in which a cIaR allele is present in truncated (inactive) 23S rRNA gene in a plasmid vector, along with the duplicate expressed chromosomal 23S rRNA genes. Genetic exchange between different HP strains, and the importance of a mutS-like possible mismatch correction function will also be studied. Third, we will seek to better understand the control of mutation in HP, and test whether Mtz therapy itself is mutagenic. Sensitive genetic tests will be used to assess the mutagenic potency of Mtz in HP in culture and in mouse models. Fourth, we will seek to more fully understand mechanisms of drug resistance in HP. We will assess whether any significant fraction of MtzR and CIaR HP isolates from as yet unstudied human populations (India, China, minorities in the US) acquire resistance by mechanisms that are distinct from rdxA inactivation (MtzR) or 23S rRNA mutation (CIaR), the mechanisms found to underly resistance in the mainstream US population.

幽门螺杆菌（Helicobacter pylori，HP）是引起消化性溃疡的主要原因，也是胃癌的早期危险因素。 两种最广泛使用的抗HP疗法依赖于甲硝唑（Mtz）或克拉霉素（Cla）与其他药物的组合，但对Mtz的耐药性（R）很常见，并且也已知ClaR。 在美国和欧洲人群中占主导地位的耐药机制已被确定：硝基还原酶基因rdxA（MtzR）的失活;和23 S rRNA的一个片段的序列变化。 我们对MtzR的分析表明，Mtz是一种前药，由MtzS HP活化（代谢）为羟胺、诱变剂和杀菌剂。HP是一个非常多样化的物种，每个分离株都很容易与大多数其他分离株区分开来。 在HP基因组中存在许多重复和不同的基因。 我们认为，这些基因之间的重组，不同的HP菌株之间的基因转移，突变，都可以有助于细菌适应不同的人类宿主和在不断变化的胃环境，更普遍的毒力的演变。我的长期目标是了解HP如何在人类宿主中定植，建立持续数年或数十年的感染，并在某些情况下导致明显的疾病;它如何演变为人类病原体;以及如何最好地对抗它引起的感染。 提出了四组实验：首先，我们将寻求更好地了解HP人群中耐药性的出现和持续。 在这些实验中，我们将测试导致MtzR和/或CIaR的突变在培养物中和在小鼠感染模型中体内降低细菌适应性（生长活力）的想法。 其次，我们将研究影响HP中重组体形成的因素，特别关注重复和分歧基因。 这将使用CIaR的等位基因进行建模，CIaR存在于23 S rRNA基因中;每个HP基因组有两个拷贝的23 S rRNA基因。 我们将检查HP向CIaR的转化，并测试确定给定HP菌株在cIaR和cIaS等位基因杂合时是否可以表现出CIaR表型的因素，以及是否必须是cIaR/cIaR纯合的因素。 还将使用“合成的部分接合子”来检查重组，其中cIaR等位基因存在于质粒载体中截短的（失活的）23 S rRNA基因中，沿着重复表达的染色体23 S rRNA基因。 还将研究不同HP菌株之间的遗传交换，以及类似mutS的可能的错配校正功能的重要性。 第三，我们将寻求更好地了解HP中突变的控制，并测试Mtz治疗本身是否具有致突变性。 将使用敏感性遗传试验评估Mtz在培养物和小鼠模型中对HP的致突变效力。 第四，我们将寻求更全面地了解HP的耐药性机制。 我们将评估来自尚未研究的人群（印度、中国、美国少数民族）的MtzR和CIaR HP分离株中是否有任何显著部分通过与rdxA失活（MtzR）或23 S rRNA突变（CIaR）不同的机制获得耐药性，这些机制是美国主流人群中耐药性的基础。